HIIFS
ACAD icon

Harel Insurance Investments & Financial Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-150
Closed -$5K – 466
2016
Q2 		$5K Buy
+150
New +$5.02K ﹤0.01% 617

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Harel Insurance Investments & Financial Services's ACAD Position: Q3 2016 in Review

Harel Insurance Investments & Financial Services sold out of Acadia Pharmaceuticals (ACAD) in Q3 2016, closing a stake of 150 shares — an estimated $5K sold.

Harel Insurance Investments & Financial Services first reported a position in ACAD in Q2 2016 and held it in 1 quarter. The position peaked at $5K in Q2 2016. 233 funds tracked by Wall St. Rank hold ACAD as of Q3 2016.

  • Harel Insurance Investments & Financial Services reported no remaining Acadia Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 150 Acadia Pharmaceuticals shares in Q3 2016, an estimated $5K.
  • Harel Insurance Investments & Financial Services first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Acadia Pharmaceuticals position peaked at $5K in Q2 2016.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2016.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q3 2016, filed 14 Nov 2016.